CSIMarket
 
Infinity Pharmaceuticals Inc   (INFI)
Other Ticker:  
 
 
Price: $0.0080 $-0.01 -50.000%
Day's High: $0.0112 Week Perf: -61.9 %
Day's Low: $ 0.01 30 Day Perf: -90.91 %
Volume (M): 2,477 52 Wk High: $ 0.26
Volume (M$): $ 20 52 Wk Avg: $0.15
Open: $0.01 52 Wk Low: $0.01



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 90
 Employees 23
 Revenues (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) -41
 Cash Flow (TTM) (Millions $) -42
 Capital Exp. (TTM) (Millions $) 0

Infinity Pharmaceuticals Inc

We are an innovative biopharmaceutical company dedicated to developing best-in-class medicines for patients with difficult-to-treat diseases. We combine proven scientific expertise with a passion for developing novel small molecule drugs that target disease pathways for potential applications in oncology.

We are focusing our efforts on our lead product candidate, IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma, or PI3K-gamma.


Role of PI3K-gamma in Cancer Growth and Survival
The body’s immune system is responsible for fighting off infections and disease, including cancer, and helping the body to heal. The immune system functions by identifying and destroying foreign cells and substances within the body. When confronted by pathogens or disease, an early response of the bodys immune system comes in the form of macrophages, a type of white blood cell that produces pro-inflammatory proteins called cytokines. These cytokines activate T cells, another type of immune cell, to attack the health threat. The macrophages then switch gears to produce other types of cytokines that dampen T cell activation, which, in turn, stimulates repair of the affected tissue.


Cancer cells arise from normal cells that have changed in a way that allows them to grow out of control. Cancer cells are not always recognized by the immune system as foreign cells that should be destroyed. However, if cancer cells are recognized by the immune system, mechanisms exist to dampen this immune response and include upregulation of “checkpoint proteins” on T cells, such as programmed death receptor 1, or PD-1. Additionally, in cancer there exists a tumor microenvironment, or TME, which refers to the non-cancerous cells present in the tumor. Cells within the TME, including macrophages, can suppress the immune response and provide signals to cancer cells allowing the tumor to grow. The presence of the supportive TME is thought to be one reason why some cancer therapies, including checkpoint inhibitors, have not provided durable or effective results to date. Targeting cells that suppress the immune system represents an emerging approach within the field of cancer immunotherapy, and inhibition of PI3K-gamma by IPI-549 represents a novel approach to targeting this immune-suppressive microenvironment.

Preclinical research found that macrophage PI3K-gamma signaling promotes a genetic program that results in a macrophage type that suppresses the activation of anti-tumor T cells. Preclinical data demonstrated that blockade of PI3K-gamma by treatment with IPI-549 leads to a shift in the type of macrophages present in the TME from macrophages associated with suppression of the immune response, known as the M2 phenotype, to macrophages that are supportive of a pro-inflammatory, anti-tumor immune response, known as the M1 phenotype. Treatment with IPI-549 increased the M1/M2 macrophage ratio, the number of T cells that attack the tumor, and the production of pro-inflammatory cytokines.

In recent years, checkpoint inhibitors have shown promising results as a treatment for multiple types of cancer, but many patients eventually become resistant to checkpoint inhibitors and require treatment with an additional therapy. Preclinical studies in a number of tumor models showed that resistance to checkpoint inhibition is associated with increased numbers of tumor-associated macrophages and is directly mediated by the immune-suppressive activity of these macrophages on T cells. Furthermore, the data showed that inhibition of PI3K-gamma by IPI-549 switched the activation of macrophages from an immune-suppressive M2 state to a pro-inflammatory M1 state, leading to enhanced anti-tumor cytotoxic T cell activity, particularly when combined with checkpoint inhibitors. These data demonstrate that IPI-549 treatment is able to reverse the lack of response to checkpoint inhibitors in models that are initially insensitive to checkpoint inhibition as a single therapy




   Company Address: 1100 Massachusetts Avenue Cambridge 2138 MA
   Company Phone Number: 453-1000   Stock Exchange / Ticker: NASDAQ INFI
   INFI is expected to report next financial results on March 27, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Infinity Pharmaceuticals Inc

Infinity Pharmaceuticals Inc battles against a crushing -15.015% revenue drop in the face of a tumultuous business climate

In the financial news report for the April to June 30, 2023 interval, Infinity Pharmaceuticals Inc managed to improve its financial status by reducing losses on diminishing revenue. The company experienced a decrease in per share shortfall, with a decrease from $-0.13 to $-0.11, demonstrating an upward trend. Additionally, the revenue decreased by -15.015% to $0.58 million, compared to $0.69 million in the same quarter of the previous year.
Compared to the preceding fiscal period, there was also an improvement in income per share, with a decrease from $-0.12 per share. However, the revenue fell by -20.246% from $0.73 million. These figures indicate that Infinity Pharmaceuticals Inc has been managing to cut its losses and improve its financial performance.

Infinity Pharmaceuticals Inc

Infinity Pharmaceuticals Inc. Struggles with Financial Losses, but Shows Promising Revenue Growth in Q1 2023

Infinity Pharmaceuticals Inc, a healthcare sector company, recorded a cumulative net loss of $-43 million during the 12 months ending in the first quarter of 2023. This resulted in a negative return on assets (ROA) of -92.41%. However, 370 other companies in the healthcare sector had a higher ROA, indicating that the company's financial performance is weaker than its competitors.
Despite the negative result, there was a significant improvement in the ROA ranking of Infinity Pharmaceuticals Inc. The overall ranking increased from 4878 in the fourth quarter of 2022 to 2275 in the first quarter of 2023. This suggests that the company's financial performance is improving, but still has a long way to go to compete effectively with its peers.
In terms of revenue, Infinity Pharmaceuticals Inc reported an increase of 12.117% from the comparable reporting season a year before, generating $0.73 million in the first quarter of 2023. However, the company still recorded a loss of $-0.12 per share, indicating that its revenue growth was not sufficient to cover its costs.
Looking at the previous reporting season, revenue surged by 34.622% from $0.54 million, but the deficit from $-0.10 per share increased. It is important to note that the customers of Infinity Pharmaceuticals Inc are looking for reliability and a good deal. Therefore, the organization needs to make a more significant effort to convince their customers of its value.
Despite reporting a net deficit of $-11.045 million for the January to March 31, 2023 interval, Infinity Pharmaceuticals Inc was able to reduce the deficit from the comparable reporting season a year ago, which was $-12.436 million. This improvement is a positive sign but the company will need to continue making progress in the future to successfully compete in the industry.






 

Infinity Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com